{
    "Trade/Device Name(s)": [
        "Total Bilirubin2"
    ],
    "Submitter Information": "Abbott Ireland Diagnostics Division",
    "510(k) Number": "K223324",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121985"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG",
        "MQM"
    ],
    "Summary Letter Date": "October 27, 2022",
    "Summary Letter Received Date": "October 31, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total Bilirubin (conjugated and unconjugated)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Serum separator tube",
        "Dipotassium EDTA tube",
        "Lithium heparin tube",
        "Lithium heparin separator tube",
        "Sodium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c System",
        "ARCHITECT c8000 System"
    ],
    "Method(s)/Technology(ies)": [
        "Diazo reaction",
        "Automated clinical chemistry assay"
    ],
    "Methodologies": [
        "Diazonium salt"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Total Bilirubin2 assay for quantitative measurement of total bilirubin in human serum or plasma on ARCHITECT c System",
    "Indications for Use Summary": "Used for quantitation of total bilirubin in adult and neonatal human serum or plasma to aid in diagnosis and management of liver, hematologic, metabolic disorders, neonatal jaundice, and hemolytic disease of the newborn on the ARCHITECT c System",
    "fda_folder": "Clinical Chemistry"
}